Canada's MediPharm Labs reports positive Q1 adjusted EBITDA

Medipharm Labs

13/05/2026 12:41

Overview

Canada cannabinoid drugmaker's Q1 revenue was C$9 mln with gross margin of 37%

Company achieved positive adjusted EBITDA, up from negative in prior quarter

Operating expenses fell 28% from Q4 2025 due to restructuring and cost control

Outlook

MediPharm Labs to prioritize margin accretive products and sustainable profitability over short-term opportunities

Result Drivers

INTERNATIONAL GROWTH - Co said international medical revenue accounted for 51% of total revenue, with new agreements in France and Brazil and sequential revenue growth in Germany

COST CONTROL - Operating expenses decreased 28% from Q4 2025, reflecting restructuring actions and cost discipline

PRODUCT MIX - Gross margin of 37% attributed to disciplined product mix and focus on margin-accretive products

Company press release: ID:nGNX2N04ZG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
C$9 mln
C$8.70 mln (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)